Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1302-1308

  Harada, Koji ^a   Ferdous, Tarannum ^a   Ueyama, Yoshiya ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Epithelial to mesenchymal transition; Oral squamous cell carcinoma; Resistance

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CADHERIN; FLUOROURACIL; TRANSCRIPTION FACTOR TWIST;

ANIMAL; APOPTOSIS; BIOSYNTHESIS; CANCER TRANSPLANTATION; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOUSE; MOUTH NEOPLASMS; NICK END LABELING; NUDE MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TWIST TRANSCRIPTION FACTOR;

EID: 84894489576     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2270     Document Type: Article

References (30)

1. Rautava J, Luukkaa M, Heikinheimo K, Alin J, Grenman R and Happonen RP: Squamous cell carcinomas arising from different types of oral epithelia differ in their tumor and patient characteristics and survival. Oral Oncol 43: 911-919, 2007. (Pubitemid 47369255)
2. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK and Hoffman HT: Presentation, treatment, and outcome of oral cavity cancer: a national cancer data base report. Head Neck 24: 165-180, 2002. (Pubitemid 34111514)
3. Mehrotra R, Singh MK, Pandya S and Singh M: The use of an oral brush biopsy without computer - assisted anaylsis in the oral lesions: a study of 94 patients. Oral Sura Oral Med Oral Pathol Oral Radiol Endod 106: 246-253, 2008.
4. Lawoyin JO, Lawoyin DO and Aderinokun G: Intra-oral squamous cell carcinoma in Ibadan: a review of 90 cases. Afr J Med Med Sci 26: 187-188, 1997.
5. Chaudhuri NK, Montag BJ and Heidelberger C: Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo. Cancer Res IS: 318-328, 1958.
6. Greenburg G and Hay ED: Epithelia suspended in collagen aels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 95: 333-339, 1982. (Pubitemid 13197104)
7. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic oxali-platin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12: 4147-4153, 2006.
8. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
9. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
10. Thiery JP and Chopin D: Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev 18: 31-42, 1999. (Pubitemid 29411090)
11. Kong B, Michalski CW and Kleeff J: Tumor initiating cells in pancreatic cancer: A critical view. World J Stem Cells 1: 8-10, 2009.
12. Gupta PB. Chaffer CL and Weinberg RA: Cancer stem cells: mirage or reality? Nat Med 15: 1010-1012, 2009.
13. Lee JH, Kim MC, Oh SY, Kwon HC, Kim SH, Kwon KA, Lee S, Jeong JS, Choi SR and Kim HJ: Predictive value of in vitro adenosine triphosphate-based chemotherapy response assay in advanced gastric cancer patients who received oral 5-fluorouracil after curative resection. Cancer Res Treat 43: 117-123, 2011.
14. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH and Larra FG: Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77: 441-451, 1996. (Pubitemid 26047564)
15. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H and Sueda T: Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. J Gastrointest Sure 13: 85-92, 2009.
16. Huang CL, Yokomise H, Kobayashi S, Fukushima M, Hitomi S and Wada H: Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 17: 47-54, 2000.
17. Furusaka T, Asakawa T, Tanaka A, Matsuda H and Ikeda M: Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer. Acta Otolarynaol 132: 1108-1114, 2012.
18. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE and Posner MR; TAX 324 Study Group: Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12: 153-159, 2011.
19. Blanchard P, Bourhis J, Lacas B, Posner MR. Vermorken JB, Hernandez JJ, Bourredjem A, Calais G, Paccasnella A, Hitt R, Pignon JP; Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group: Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 31: 2854-2860, 2013.
20. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ and Pinedo HM: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587: 194-205, 2002. (Pubitemid 34655788)
21. Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003. (Pubitemid 37328853)
22. Harada K, Kawashima Y, Yoshida H and Sato M: Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1. Oncol Rep 15: 1417-1423, 2006.
23. Johnston PG, Drake JC, Trepel J and Allegra CJ: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52: 4306-4312, 1992.
24. Plasencia C, Rooney PH, Taron M, Martinez-Balibrea E, McLeod HL and Abad A: Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms. Int J Oncol 22: 945-953, 2003.
25. Tanaka T, Bai T and Toujima S: Establishment and characterization of monoclonal 5-fluorouracil-resistant cell lines derived from human endometrial adenocarcinoma. Int J Oncol 37: 731-736, 2010.
26. Uchibori K, Kasamatsu A, Sunaga M, Yokota S, Sakurada T, Kobayashi E, Yoshikawa M, Uzawa K, Ueda S, Tanzawa H and Sato N: Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol 40: 1005-1010, 2012.
27. Nagata M, Nakayama H, Tanaka T, Yoshida R, Yoshitake Y, Fukuma D, Kawahara K, Nakaaawa Y, Ota K, Hiraki A and Shinohara M: Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma. Br J Cancer 105: 1322-1330, 2011.
28. Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428, 2007. (Pubitemid 46809165)
29. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W III and Dantzig AH: The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its mono-phosphorvlated metabolites. Mol Cancer Ther 4: 855-863, 2005. (Pubitemid 40767130)
30. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T and Kohgo Y: Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 96: 457-463, 2007. (Pubitemid 46215217)